Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 4/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.49 |
| ▸ | MARK3 | P27448 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | CDK1 | P06493 | 3/20 | 0.49 |
| ▸ | LYN | P07948 | 3/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.49 |
| ▸ | IGF1R | P08069 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | BLK | P51451 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.49 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4409376 | 0.83 | KDR (0.48) | CDK2CDK1IGF1RKDRFLT3 | |
| Hydrochloric Acid SCHEMBL7659966 | 0.81 | CDK1 (0.58) | CDK2CDK1IGF1RJAK2PDPK1 | |
| SCHEMBL4551624 | 0.80 | FLT3 (0.44) | CDK2CDK1KDRFLT3PTK2 | |
| SCHEMBL1019383 | 0.78 | IP6K1 (0.47) | CDK2CDK1CYP1A2MAPK1KMT2A | |
| SCHEMBL3014784 | 0.77 | SYK (0.60) | CDK2CDK1CDK5CLK4SYK | |
| SCHEMBL3016793 | 0.77 | CDK1 (0.57) | CDK2GSK3BMARK3AURKACDK1 | |
| SCHEMBL8542827 | 0.76 | HDAC6 (0.44) | CDK2RPS6KB1IGF1RCYP3A4TSHR | |
| SCHEMBL6446927 | 0.75 | CDK2 (1.00) | CDK2GSK3BMARK3AURKACDK1 | |
| SCHEMBL31339126 | 0.75 | RAB9A (0.38) | CDK2GSK3BIGF1RGSK3ACDK5 | |
| SCHEMBL15380926 | 0.75 | CDK2 (0.54) | CDK2GSK3BMARK3AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | PALAU PHARMA, S.A. (ES) | 2010-08-12 | — | — | US | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-19 | — | — | US | disclosed |
| WO-2002102769-A2 | METHODS FOR SYNTHESIZING SUBSTITUTED PYRIMIDINES | UNIVERSITY OF MASSACHUSETTS (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204187-A1 | Purine Derivatives | JAK3, JAK1, JAK2 | CDK2 137/4885GSK3B 956/4885MARK3 342/4885 |
| US-20030114414-A1 | Methods for synthesizing substituted pyrimidines | TYMP, NUDT1, TYMS | CDK2 151/4885GSK3B 4828/4885MARK3 4282/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CDK2 13/4885GSK3B 163/4885MARK3 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.